Adbry is the brand name for tralokinumab-ldrm. It is approved for the treatment of atopic dermatitis, commonly referred to as eczema, a chronic skin condition characterized by itching, redness, and inflammation. Adbry is approved for those with moderate-to-severe atopic dermatitis who have not responded well to other treatments.
Tralokinumab is a monoclonal antibody, a type of biologic drug designed to target specific molecules in the immune system. Adbry works by inhibiting the activity of a molecule called interleukin-13 (IL-13), which is involved in the inflammatory response in atopic dermatitis. By blocking the action of IL-13, tralokinumab helps to reduce the inflammation and symptoms associated with the condition. It is similar in use to another biologic called Dupixent (Dupilumab). Adbry can be used with or without topical corticosteroids. This medication is typically given as a subcutaneous injection, meaning it’s injected just beneath the skin, typically every two or four weeks.
Clinical trials have shown that tralokinumab can lead to a significant reduction in the severity of atopic dermatitis symptoms, including itching and inflammation. It can also improve the quality of life for those suffering from this condition.
Like all medications, Adbry may have potential side effects, which can vary from person to person. Common side effects may include injection site reactions, upper respiratory tract infections, and conjunctivitis. It’s essential to discuss potential side effects and safety concerns with your dermatologist.
If you are considering Adbry as a treatment option for atopic dermatitis, it is important to consult with a dermatologist.
Contact SOMA Skin & Laser to schedule a consultation today.
973-763-7546
